Therapeutics will move offices during the 2H 2013. ACT has committed
to become tenants in The Nucleus, located at 300 East Market Street,
Louisville, KY 40202, the newest building in the Nucleus Innovation
Park complex in downtown Louisville.
ACT strengthens its PFKFB3 drug discovery program with the following
U.S. granted intellectual property: U.S. Patent 8,088,385 B2
titled “PFKFB3 inhibitor for the treatment of a Proliferative
Cancer" granted April 3, 2012.
ACT submits IND application to FDA: Advanced Cancer Therapeutics
electronically submitted an Investigational New Drug (IND)
Application for PFKFB3 to the Food and Drug Administration
(FDA) on November 28,
ACT received both Federal and State of Kentucky matching
grants for its PFKFB3 drug discovery program: On December 22, 2012,
Advanced Cancer Therapeutics was awarded funds through
the Kentucky’s SBIR-STTR Matching Funds Award Program. The $150,000
grant is for a Glioblastoma Multifomra (GBM) Phase I Study.
ACT obtains key cancer metabolism target intellectual
property: U.S. Granted Patent 8,283,332 B2 granted
October 9, 2012 titled “PFKFB4 Inhibitors and Methods
of Using the Same ”.
ACT obtains intellectual property
for cancer product platform technology (Terigo™): U.S.
Granted Patent 8,410,070 B2 granted on April 12, 2013
Compositions and Methods for Treating Cancer, Inhibiting
Proliferation, and Inducing Cell Death”.